This Day On The Street
Continue to site right-arrow
ADVERTISEMENT
This account is pending registration confirmation. Please click on the link within the confirmation email previously sent you to complete registration.
Need a new registration confirmation email? Click here

Royalty Pharma Acceptances Announcement

NEW YORK, June 11, 2013 /PRNewswire/ -- In accordance with Rule 17.1 and Rule 2.9 of the Irish Takeover Rules and Rule 14e-1 of the US Exchange Act, Echo Pharma Acquisition Limited ("Royalty Pharma") today announced acceptance levels of its Further Increased Offer for Elan Corporation, plc (NYSE: ELN).

Background

On 2 May 2013, Echo Pharma Acquisition Limited ("Royalty Pharma") made an offer for the entire of the issued and to be issued share capital of Elan Corporation, plc ("Elan") (the "Original Offer").

On 20 May 2013, Royalty Pharma announced the terms of a revision to the Original Offer (the "Increased Offer"). The Increased Offer was made on 23 May 2013 and was an all cash offer of US$12.50 per Elan Share (including each Elan Share represented by an Elan ADS). The full terms of, and conditions to, the Increased Offer and the procedure for acceptance were set out in the revised offer document despatched by Royalty Pharma on 23 May 2013 (the "Revised Offer Document").  The initial closing date for the Increased Offer, as set out in the Revised Offer Document, was 1:00 p.m. (Irish time) / 8:00 a.m. ( New York City time) on 6 June 2013 (unless extended).

On 6 June 2013, Royalty Pharma announced that the closing date for the Increased Offer was extended until 1:00 p.m. (Irish time) / 8:00 a.m. ( New York City time) on Friday, 21 June 2013 and would remain open for acceptance until that time (unless further extended).

On 7 June 2013, Royalty Pharma announced the terms of a further revision to the Increased Offer (the "Further Increased Offer"). The Further Increased Offer was made on 10 June 2013 and is an offer of US$13.00 in cash per Elan Share (including each Elan Share represented by an Elan ADS) plus a contingent value right ("CVR") worth up to US$2.50 per share upon the achievement of certain CVR Payment Events that are set out in the further revised offer document despatched by Royalty Pharma on 10 June 2013 (the "Further Revised Offer Document"). The full terms of, and conditions to, the Further Increased Offer and the procedure for acceptance are set out in the Further Revised Offer Document.  The closing date for the Further Increased Offer, as set out in the Further Revised Offer Document, has been extended until 1:00 p.m. (Irish time) / 8:00 a.m. ( New York City time) on Monday, 24 June 2013 and will remain open for acceptance until that time (unless further extended).

A reference in this announcement to the "Offer" means the Original Offer (including where the context so requires, any subsequent revision, variation, extension or renewal of the Original Offer, including in connection with the Increased Offer and the Further Increased Offer). Capitalised terms used but not defined in this announcement shall have the meaning given to them in the Further Revised Offer Document.

1 of 7

Check Out Our Best Services for Investors

Action Alerts PLUS

Portfolio Manager Jim Cramer and Director of Research Jack Mohr reveal their investment tactics while giving advanced notice before every trade.

Product Features:
  • $2.5+ million portfolio
  • Large-cap and dividend focus
  • Intraday trade alerts from Cramer
Quant Ratings

Access the tool that DOMINATES the Russell 2000 and the S&P 500.

Product Features:
  • Buy, hold, or sell recommendations for over 4,300 stocks
  • Unlimited research reports on your favorite stocks
  • A custom stock screener
Stocks Under $10

David Peltier uncovers low dollar stocks with serious upside potential that are flying under Wall Street's radar.

Product Features:
  • Model portfolio
  • Stocks trading below $10
  • Intraday trade alerts
14-Days Free
Only $9.95
14-Days Free
To begin commenting right away, you can log in below using your Disqus, Facebook, Twitter, OpenID or Yahoo login credentials. Alternatively, you can post a comment as a "guest" just by entering an email address. Your use of the commenting tool is subject to multiple terms of service/use and privacy policies - see here for more details.
Submit an article to us!
SYM TRADE IT LAST %CHG

Markets

DOW 17,698.18 -77.94 -0.44%
S&P 500 2,059.69 -8.20 -0.40%
NASDAQ 4,880.2280 -20.6570 -0.42%

Partners Compare Online Brokers

Free Reports

Top Rated Stocks Top Rated Funds Top Rated ETFs